Clot-Busting Drug THR-100 (Staphylokinase) Enters Phase III Clinical Trials in India
Thrombolytic Agent for Treatment of Myocardial Infarction
Being Developed for Emerging Markets by Bharat Biotech
Leuven, Belgium and Hyderabad, India – 4 February 2011 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its partner, Bharat Biotech International Limited (Hyderabad, India), has initiated a Phase III trial in India with THR-100 in patients suffering an acute myocardial infarction (AMI or heart attack). Bharat Biotech is a leading innovator and manufacturer of vaccines and biologics with focus on emerging markets. The trial is expected to recruit approximately 120 patients.